Yuhua Bao1, Renee C Maciejewski2, Melissa M Garrido3, Manish A Shah4, Paul K Maciejewski5, Holly G Prigerson6. 1. Department of Healthcare Policy & Research, Weill Cornell Medical College, New York, New York, USA; Department of Psychiatry, Weill Cornell Medical College, New York, New York, USA. Electronic address: yub2003@med.cornell.edu. 2. Center for Research on End-of-Life Care, Weill Cornell Medical College, New York, New York, USA. 3. Department of Geriatrics and Palliative Medicine, Mount Sinai School of Medicine, New York, New York, USA; James J Peters Veterans Affairs Medical Center, Bronx, New York, USA. 4. Medical Oncology/Solid Tumor Program, Meyer Cancer Center at Weill Cornell Medicine, New York, New York, USA. 5. Center for Research on End-of-Life Care, Weill Cornell Medical College, New York, New York, USA; Department of Radiology, Weill Cornell Medical College, New York, New York, USA; Division of Geriatrics and Palliative Medicine, Department of Medicine, Weill Cornell Medical College, New York, New York, USA. 6. Center for Research on End-of-Life Care, Weill Cornell Medical College, New York, New York, USA; Division of Geriatrics and Palliative Medicine, Department of Medicine, Weill Cornell Medical College, New York, New York, USA.
Abstract
CONTEXT: For patients with metastatic cancer and limited life expectancy, potential benefits of chemotherapy must be balanced against harms to quality of life near death and increased out-of-pocket costs of care. OBJECTIVES: To evaluate the association between chemotherapy use by patients with Stage IV pancreatic cancer and health care use and Medicare and out-of-pocket costs in the last 30 days of life. METHODS: We conducted a retrospective cohort study of 3825 patients aged 66 years or older when diagnosed with Stage IV pancreatic cancer in 2006-2011, using the linked Surveillance, Epidemiology, and End Results-Medicare data. Using a propensity score matched sample, we examined associations between initiation of chemotherapy shortly after the metastatic diagnosis (and secondarily, continued chemotherapy use in the last 30 days of life) and health care use and costs (both Medicare payment and patient out-of-pocket costs) in the last 30 days of life. RESULTS: Chemotherapy use was associated with increased rates of hospital admissions (45.0% vs. 29.2%, P < 0.001), emergency department visits (41.3% vs. 27.2%, P < 0.001), and death in a hospital (14.2% vs. 9.1%, P < 0.001); fewer days in hospice care (11.5 days vs. 15.7 days, P < 0.001); and more than 50% increase in patient out-of-pocket costs for care ($1311.5 vs. $841.0, P < 0.001) in the last 30 days of life. Among patients who initiated chemotherapy, more stark differences in these outcomes were found by whether patients received chemotherapy in the last 30 days of life. CONCLUSION: Chemotherapy use among older patients diagnosed with metastatic pancreatic cancer was associated with substantially increased use of health care and higher patient out-of-pocket costs near death.
CONTEXT: For patients with metastatic cancer and limited life expectancy, potential benefits of chemotherapy must be balanced against harms to quality of life near death and increased out-of-pocket costs of care. OBJECTIVES: To evaluate the association between chemotherapy use by patients with Stage IV pancreatic cancer and health care use and Medicare and out-of-pocket costs in the last 30 days of life. METHODS: We conducted a retrospective cohort study of 3825 patients aged 66 years or older when diagnosed with Stage IV pancreatic cancer in 2006-2011, using the linked Surveillance, Epidemiology, and End Results-Medicare data. Using a propensity score matched sample, we examined associations between initiation of chemotherapy shortly after the metastatic diagnosis (and secondarily, continued chemotherapy use in the last 30 days of life) and health care use and costs (both Medicare payment and patient out-of-pocket costs) in the last 30 days of life. RESULTS: Chemotherapy use was associated with increased rates of hospital admissions (45.0% vs. 29.2%, P < 0.001), emergency department visits (41.3% vs. 27.2%, P < 0.001), and death in a hospital (14.2% vs. 9.1%, P < 0.001); fewer days in hospice care (11.5 days vs. 15.7 days, P < 0.001); and more than 50% increase in patient out-of-pocket costs for care ($1311.5 vs. $841.0, P < 0.001) in the last 30 days of life. Among patients who initiated chemotherapy, more stark differences in these outcomes were found by whether patients received chemotherapy in the last 30 days of life. CONCLUSION: Chemotherapy use among older patients diagnosed with metastatic pancreatic cancer was associated with substantially increased use of health care and higher patient out-of-pocket costs near death.
Authors: Gery P Guy; Donatus U Ekwueme; K Robin Yabroff; Emily C Dowling; Chunyu Li; Juan L Rodriguez; Janet S de Moor; Katherine S Virgo Journal: J Clin Oncol Date: 2013-09-16 Impact factor: 44.544
Authors: Mary Ersek; Susan C Miller; Todd H Wagner; Joshua M Thorpe; Dawn Smith; Cari R Levy; Risha Gidwani; Katherine Faricy-Anderson; Karl A Lorenz; Bruce Kinosian; Vincent Mor Journal: Cancer Date: 2017-04-17 Impact factor: 6.860
Authors: Lucia C Petito; Xabier García-Albéniz; Roger W Logan; Nadia Howlader; Angela B Mariotto; Issa J Dahabreh; Miguel A Hernán Journal: JAMA Netw Open Date: 2020-03-02
Authors: Angela C Tramontano; Yufan Chen; Tina R Watson; Andrew Eckel; Deirdre F Sheehan; Mary Linton B Peters; Pari V Pandharipande; Chin Hur; Chung Yin Kong Journal: Medicine (Baltimore) Date: 2019-12 Impact factor: 1.889
Authors: Mohemmed N Khan; Katrina Hueniken; Mirko Manojlovic-Kolarski; Lawson Eng; Maryam Mirshams; Khaleeq Khan; Colleen Simpson; Michael Au; Geoffrey Liu; Wei Xu; Christopher J Longo; David P Goldstein; Jolie Ringash; Rosemary Martino; Aaron R Hansen; John R de Almeida Journal: Cancer Rep (Hoboken) Date: 2021-08-24